Onfi Lawyers

Onfi Warning

FDA Warning Links Onfi to Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

December 3, 2013—The Federal Food and Drug Administration (FDA) warned of serious skin reactions associated with Onfi (clobazam) and announced labeling changes reflecting these side effects. The FDA reported that people taking Onfi are at risk of developing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

The incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis is most prevalent during the first eight week of treatment or when the medication is stopped and then resumed. The labeling for FDA has been changed to identify these serious side effects.

About Onfi

Onfi belongs to a class of drugs known as benzodiazepines which used in conjunction with other medications to treat seizures in people diagnosed with Lennox-Gastaut Syndrome, a severe form of epilepsy. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis generally are not associated with benzodiazepines.

If you have experienced serious skin reactions after taking Onfi, including developing a rash, blistering or peeling of the skin, mouth sores or hives, promptly consult your physician for an evaluation.

If you have developed Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis after taking Onfi, you may be entitled to compensation. You should act immediately to contact an attorney experienced in matters involving defective pharmaceuticals.